CAMP4 Therapeutics (CAMP) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for CAMP4 Therapeutics (CAMP).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||
Total Revenue | 1.29M (+268.57%) | 350K (-56.25%) | 800K (-46.67%) | 1.50M (+74.42%) | 860K (+32.31%) | 650K | - | - | - | - | 350K | - | - |
Operating Expenses | |||||||||||||
Research And Development | 10M (+21.53%) | 8.36M (-10.68%) | 9.36M (-9.48%) | 10M (+1.87%) | 10M (+1.60%) | 9.99M (+2.99%) | 9.70M (+3.30%) | 9.39M (-3.59%) | 9.74M (-68.38%) | 31M (+213.65%) | 9.82M | - | - |
Selling General And Administrative | 4.21M (-11.74%) | 4.77M (+3.70%) | 4.60M (+10.05%) | 4.18M (+9.71%) | 3.81M (-18.94%) | 4.70M (+23.36%) | 3.81M (+16.51%) | 3.27M (+4.14%) | 3.14M (-64.07%) | 8.74M (+204.53%) | 2.87M | - | - |
Operating Expenses | 14M (+9.53%) | 13M (-9.20%) | 14M (-0.55%) | 15M (+4.08%) | 14M (-4.97%) | 15M (+8.65%) | 14M (+6.79%) | 13M (-1.71%) | 13M (-67.43%) | 40M (+211.58%) | 13M | - | - |
Depreciation And Amortization | 520K (+23.81%) | 420K (+5.00%) | 400K (0.00%) | 400K (-4.76%) | 420K (-8.70%) | 460K (+15.00%) | 400K (0.00%) | 400K (-9.09%) | 440K (-65.63%) | 1.28M (+220.00%) | 400K | - | - |
Operating Income | |||||||||||||
Operating Income | -13.07M (+2.27%) | -12.78M (-6.37%) | -13.65M (+4.76%) | -13.03M (-0.53%) | -13.10M (-6.63%) | -14.03M (+3.77%) | -13.52M (+6.79%) | -12.66M (-1.63%) | -12.87M (-67.45%) | -39.54M (+220.42%) | -12.34M | - | - |
Ebit | -13.07M (+2.27%) | -12.78M (-6.37%) | -13.65M (+4.76%) | -13.03M (-0.53%) | -13.10M (-6.63%) | -14.03M (+3.77%) | -13.52M (+6.79%) | -12.66M (-1.63%) | -12.87M (-13.80%) | -14.93M (+20.99%) | -12.34M (+1.98%) | -12.10M (-3.28%) | -12.51M |
EBITDA | -12.55M (+1.54%) | -12.36M (-6.72%) | -13.25M (+4.91%) | -12.63M (-0.39%) | -12.68M (-6.56%) | -13.57M (+3.43%) | -13.12M (+7.01%) | -12.26M (-1.45%) | -12.44M (-8.93%) | -13.66M (+14.41%) | -11.94M (-1.32%) | -12.10M (-3.28%) | -12.51M |
Other Income / Expenses | |||||||||||||
Interest Income | 910K (+28.17%) | 710K (+69.05%) | 420K (-6.67%) | 450K (-23.73%) | 590K (-3.28%) | 610K (+577.78%) | 90K (-60.87%) | 230K (-42.50%) | 400K (-81.13%) | 2.12M (+207.25%) | 690K | - | - |
Net Interest Income | 910K (+28.17%) | 710K (+69.05%) | 420K (-6.67%) | 450K (-23.73%) | 590K (-3.28%) | 610K (+577.78%) | 90K (-60.87%) | 230K (-42.50%) | 400K (-81.13%) | 2.12M (+207.25%) | 690K | - | - |
Other Non Operating Income | 20K | -27.85M (+39685.71%) | -70.00K (+600.00%) | -10.00K | 80K (-93.85%) | 1.30M | -60.00K (-57.14%) | -140.00K | 30K (-98.84%) | 2.59M (+304.69%) | 640K | - | - |
Net Income | |||||||||||||
Net Income From Continuing Operations | -18.33M (-54.49%) | -40.28M (+166.75%) | -15.10M (+19.94%) | -12.59M (+1.29%) | -12.43M (-6.40%) | -13.28M (-1.48%) | -13.48M (+7.24%) | -12.57M (+0.88%) | -12.46M (-4.08%) | -12.99M (+11.03%) | -11.70M (-3.31%) | -12.10M (-3.28%) | -12.51M |
Net Income | -18.33M (-54.49%) | -40.28M (+166.75%) | -15.10M (+19.94%) | -12.59M (+1.29%) | -12.43M (-6.40%) | -13.28M (-1.48%) | -13.48M (+7.24%) | -12.57M (+0.88%) | -12.46M (-4.08%) | -12.99M (+11.03%) | -11.70M (-3.31%) | -12.10M (-3.28%) | -12.51M |
Comprehensive Income Net Of Tax | -18.33M (-77.20%) | -80.40M (+432.45%) | -15.10M (+19.94%) | -12.59M (+1.29%) | -12.43M (-76.00%) | -51.79M (+284.20%) | -13.48M (+7.15%) | -12.58M (+1.04%) | -12.45M (-74.74%) | -49.29M (+321.28%) | -11.70M | - | - |